Cantor Fitzgerald Initiates Coverage On Mereo BioPharma Group with Overweight Rating, Announces Price Target of $4
Cantor Fitzgerald analyst Kristen Kluska initiates coverage on Mereo BioPharma Group (NASDAQ:MREO) with a Overweight rating and announces Price Target of $4.